Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: WFRF:(Kivisakk P) > Neutralising and bi...

Details
MARC

Kivisakk, P (author)

Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis

Article/chapterEnglish1997

Publisher, publication year, extent ...

2016-07-02
SAGE Publications,1997

Numbers

LIBRIS-ID:oai:prod.swepub.kib.ki.se:1929687
http://kipublications.ki.se/Default.aspx?queryparsed=id:1929687URI
https://doi.org/10.1177/135245859700300303DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

Interferon-β-1b (IFN-β-1b) is an immunomodulatory therapy of multiple sclerosis (MS), reducing the numbers and severity of exacerbations and the total lesion load measured by magnetic resonance imaging of the brain. The benefits of IFN-β-1b could be hampered by the development of neutralising antibodies against the compound. Our results confirmed earlier studies, showing that 42% of MS patients treated with IFN-β-1b for more than 3 months had developed neutralising antibodies. The occurrence of binding anti-IFN-β-1b antibodies, presently not believed to impede the clinical efficacy of IFN-β-1b, were demonstrated by an immunoassay in some patients already after I month of treatment and in 78% after 3 months. The development of binding antibodies seemed to be an early phenomenon, preceding the appearance of neutralising antibodies. Antibodies crossreacting with IFN-β-1a and natural IFN-β were also found in a majority of IFN-β-1b treated patients with high titres of binding antibodies. Employing a solid-phase enzyme-linked immunospot (ELISPOT) assay, 68% of MS patients treated with IFN-β-1b for 1 -23 months had elevated numbers of anti-IFN-β-1b-antibody secreting cells in blood, compared to 18% of untreated MS patients and 20% among patients with other neurological diseases. Thus, our findings confirm that IFN-β-1 b is immunogenic in MS patients. High levels of anti-IFN-β-1b antibody secreting cells were, however, also found in two untreated control patients with inflammatory diseases, suggesting that anti-IFN-β-1b antibodies might also occur spontaneously.

Added entries (persons, corporate bodies, meetings, titles ...)

Alm, GV (author)
Tian, WZ (author)
Matusevicius, D (author)
Fredrikson, SKarolinska Institutet (author)
Link, HKarolinska Institutet (author)
Karolinska Institutet (creator_code:org_t)

Related titles

In:Multiple sclerosis (Houndmills, Basingstoke, England): SAGE Publications3:3, s. 184-1901352-45851477-0970

Internet link

Find in a library

Multiple sclerosis (Houndmills, Basingstoke, England) (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

By the author/editor: Kivisakk, P; Alm, GV; Tian, WZ; Matusevicius, D; Fredrikson, S; Link, H

Articles in the publication: Multiple scleros ...

By the university: Karolinska Institutet

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se